Cargando…
Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report
RATIONALE: Peptide receptor radionuclide therapy with (177)Lu-Dotatate represents a major breakthrough in the treatment of metastatic well differentiated neuroendocrine tumors. This treatment is generally well tolerated. Reported severe long-term hematological side effects are rare and include hemat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500554/ https://www.ncbi.nlm.nih.gov/pubmed/34622868 http://dx.doi.org/10.1097/MD.0000000000027455 |
_version_ | 1784580470769451008 |
---|---|
author | Worbe, Noémie Damian, Louise Le Cam-Duchez, Véronique Levesque, Hervé Michel, Pierre Quak, Elske |
author_facet | Worbe, Noémie Damian, Louise Le Cam-Duchez, Véronique Levesque, Hervé Michel, Pierre Quak, Elske |
author_sort | Worbe, Noémie |
collection | PubMed |
description | RATIONALE: Peptide receptor radionuclide therapy with (177)Lu-Dotatate represents a major breakthrough in the treatment of metastatic well differentiated neuroendocrine tumors. This treatment is generally well tolerated. Reported severe long-term hematological side effects are rare and include hematopoietic neoplasms and bone marrow failure. PATIENTS CONCERNS: We describe the case of a patient presenting spontaneous bleeding and bruising occurring 6 weeks after the first administration of (177)Lu-Dotatate. Blood tests showed anemia, thrombocytopenia, prolonged clotting times, profound fibrinolysis and low levels of coagulation factors II and V. There were no signs of tumor lysis syndrome. DIAGNOSES: We made the diagnosis of acute disseminated intravascular coagulation. INTERVENTION: Treatment consisted of multiple transfusions of fresh frozen plasma, fibrinogen and platelets, and corticosteroids. Acute disseminated intravascular coagulation (DIC) persisted for 10 days and then resolved. OUTCOMES: Metabolic imaging 5 months after the (177)Lu-Dotatate administration showed disease progression. Treatment with 177Lu-Dotatate was not rechallenged due to the occurrence of DIC. LESSONS: Our case suggests that acute hemorrhagic disseminated intravascular coagulation can be a rare and life-threatening subacute side effect of (177)Lu-Dotatate peptide receptor radionuclide therapy. |
format | Online Article Text |
id | pubmed-8500554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-85005542021-10-12 Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report Worbe, Noémie Damian, Louise Le Cam-Duchez, Véronique Levesque, Hervé Michel, Pierre Quak, Elske Medicine (Baltimore) 5700 RATIONALE: Peptide receptor radionuclide therapy with (177)Lu-Dotatate represents a major breakthrough in the treatment of metastatic well differentiated neuroendocrine tumors. This treatment is generally well tolerated. Reported severe long-term hematological side effects are rare and include hematopoietic neoplasms and bone marrow failure. PATIENTS CONCERNS: We describe the case of a patient presenting spontaneous bleeding and bruising occurring 6 weeks after the first administration of (177)Lu-Dotatate. Blood tests showed anemia, thrombocytopenia, prolonged clotting times, profound fibrinolysis and low levels of coagulation factors II and V. There were no signs of tumor lysis syndrome. DIAGNOSES: We made the diagnosis of acute disseminated intravascular coagulation. INTERVENTION: Treatment consisted of multiple transfusions of fresh frozen plasma, fibrinogen and platelets, and corticosteroids. Acute disseminated intravascular coagulation (DIC) persisted for 10 days and then resolved. OUTCOMES: Metabolic imaging 5 months after the (177)Lu-Dotatate administration showed disease progression. Treatment with 177Lu-Dotatate was not rechallenged due to the occurrence of DIC. LESSONS: Our case suggests that acute hemorrhagic disseminated intravascular coagulation can be a rare and life-threatening subacute side effect of (177)Lu-Dotatate peptide receptor radionuclide therapy. Lippincott Williams & Wilkins 2021-10-08 /pmc/articles/PMC8500554/ /pubmed/34622868 http://dx.doi.org/10.1097/MD.0000000000027455 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 5700 Worbe, Noémie Damian, Louise Le Cam-Duchez, Véronique Levesque, Hervé Michel, Pierre Quak, Elske Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report |
title | Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report |
title_full | Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report |
title_fullStr | Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report |
title_full_unstemmed | Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report |
title_short | Hemorrhagic disseminated intravascular coagulation after (177)Lu-Dotatate in metastatic midgut neuroendocrine tumor: A case report |
title_sort | hemorrhagic disseminated intravascular coagulation after (177)lu-dotatate in metastatic midgut neuroendocrine tumor: a case report |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500554/ https://www.ncbi.nlm.nih.gov/pubmed/34622868 http://dx.doi.org/10.1097/MD.0000000000027455 |
work_keys_str_mv | AT worbenoemie hemorrhagicdisseminatedintravascularcoagulationafter177ludotatateinmetastaticmidgutneuroendocrinetumoracasereport AT damianlouise hemorrhagicdisseminatedintravascularcoagulationafter177ludotatateinmetastaticmidgutneuroendocrinetumoracasereport AT lecamduchezveronique hemorrhagicdisseminatedintravascularcoagulationafter177ludotatateinmetastaticmidgutneuroendocrinetumoracasereport AT levesqueherve hemorrhagicdisseminatedintravascularcoagulationafter177ludotatateinmetastaticmidgutneuroendocrinetumoracasereport AT michelpierre hemorrhagicdisseminatedintravascularcoagulationafter177ludotatateinmetastaticmidgutneuroendocrinetumoracasereport AT quakelske hemorrhagicdisseminatedintravascularcoagulationafter177ludotatateinmetastaticmidgutneuroendocrinetumoracasereport |